Antiviral treatment after liver cancer treatment
Part of Cancer, Digestive system, Infections clinical trials.
This study looks at whether giving antiviral medicine after liver cancer treatment helps prevent the cancer from coming back and improves overall outcomes. It is for people with hepatitis B who have had their liver cancer removed or destroyed with a procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have hepatitis B (positive for HBsAg).
- You have been diagnosed with liver cancer (hepatocellular carcinoma) and have had surgery or ablation to remove it.
- Your liver cancer is at an early stage (BCLC stage 0 or A).
- Your liver function is good (Child-Pugh class A).
- You have not had other cancer treatments like chemotherapy or targeted therapy before.
- You do not have other serious medical conditions or infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways of managing hepatitis B while you receive immunotherapy for liver cancer: one group gets a single antiviral drug (TAF), the other gets two antiviral drugs (ETV and TAF). The goal is to see which approach better supports the immunotherapy and improves outcomes.
This study tests whether a Chinese herbal medicine called Biejia-Ruangan Compound can help people with early-stage liver cancer who have already had successful treatment (surgery or ablation) live longer and keep the cancer from coming back. It is for people who also have chronic hepatitis B.
This trial studies an antiviral medicine given after surgery for liver cancer to help prevent the cancer from coming back. It focuses on people who are hepatitis B–positive (HBsAg positive) and have complete remission on follow-up checks.
This trial tests a medication (pegylated interferon alfa-2b) for people with hepatitis B-related liver cancer that has been completely removed by surgery or ablation. The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests a two-drug combination to treat chronic hepatitis B in people who have had liver cancer surgery or ablation. It aims to reduce the virus and improve liver health.
This Phase 1/2 study tests a lab-made cell treatment (SCG101) for people with hepatitis B–related liver cancer who have already had standard treatments. It aims to shrink tumors and improve outcomes in carefully selected patients.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.